Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations

Abstract

In the past decade, the available treatments for patients with acute lymphoblastic leukemia (ALL) have rapidly expanded, in parallel with an increased understanding of the genomic features that impact the disease biology and clinical outcomes. With the development of the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin, the CD3-CD19 bispecific T-cell engager antibody blinatumomab, CD19 chimeric antigen receptor T-cell therapy, and the potent BCR-ABL1 tyrosine kinase inhibitor ponatinib, the outlook of ALL in both younger and older adults has substantially improved. The availability of highly effective drugs raised important questions concerning the optimal combination and sequence of these agents, their incorporation into frontline regimens, and the role of hematopoietic stem cell transplantation. In this review, we discuss the rapidly evolving paradigms in the treatment of ALL, highlighting both established and effective regimens, as well as promising new therapies that are being evaluated in ongoing clinical trials. We specifically focus on novel combination regimens in both the frontline and salvage settings that are leading to new standards of care in the treatment of ALL.

Original languageEnglish (US)
Pages (from-to)3044-3058
Number of pages15
JournalLeukemia
Volume35
Issue number11
DOIs
StatePublished - Nov 2021

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms'. Together they form a unique fingerprint.

Cite this